Coave Therapeutics
www.coavetx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Coave Therapeutics
USANA ‘Cautiously Optimistic’ For Sales Rebound In 30th Year Despite Disappointing End To 2021
For its 2021 FY and Q4 results, nutritional and weight loss products direct seller reports lower gross margin and marketing expenses also contributed to lower-than-expected diluted EPS, down 45% to 18 cents.
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- HORAMA S.A.